Calavo Growers (CVGW) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
Mission Produce and Calavo Growers propose a merger, unanimously approved by both boards, creating a combined company with Mission Produce shareholders owning ~80% and Calavo shareholders ~20%.
Calavo shareholders will receive $14.85 in cash and 0.9790 shares of Mission Produce for each Calavo share, with the exchange ratio fixed.
The implied value of the merger consideration was $27.15 per Calavo share at announcement, a 26% premium to Calavo’s 30-day VWAP.
The merger is expected to close in Q3 2026, subject to regulatory and shareholder approvals.
Voting matters and shareholder proposals
Mission Produce shareholders will vote on issuing new shares for the merger and on potential adjournment to solicit more proxies.
Calavo shareholders will vote on the merger agreement, an advisory vote on executive compensation related to the merger, and potential adjournment.
Both boards recommend voting in favor of all proposals.
Dissenters’ rights are available to Calavo shareholders under California law.
Board of directors and corporate governance
The combined company’s board will have ten directors: nine from Mission Produce and one from Calavo.
John M. Pawlowski will become CEO of the combined company after the merger.
Both companies’ boards considered strategic alternatives and determined the merger was in the best interest of shareholders.
Latest events from Calavo Growers
- Net sales fell 21%, but Prepared segment grew 20% and merger progress continued.CVGW
Q1 202612 Mar 2026 - Deal creates a top produce platform with $25M in synergies, closing by August 2026.CVGW
M&A announcement15 Jan 2026 - Net income soared 192% year-over-year; merger with Mission Produce targets $25M synergies.CVGW
Q4 202514 Jan 2026 - Annual meeting covers director elections, auditor ratification, compensation, and equity plan extension.CVGW
Proxy Filing1 Dec 2025 - Director elections, auditor ratification, and equity plan changes up for vote at annual meeting.CVGW
Proxy Filing1 Dec 2025 - Annual meeting set for April 23, 2025, with key proposals and voting details in proxy materials.CVGW
Proxy Filing1 Dec 2025 - Prepared segment growth and legal resolutions drove improved adjusted results despite FDA-related costs.CVGW
Q3 20259 Sep 2025 - Net sales up 12%, Fresh Cut sold, debt retired, and dividend doubled on strong avocado margins.CVGW
Q3 202413 Jun 2025 - Q2 net sales up 16.5% with margin gains; Fresh Cut sale and FCPA probe remain key themes.CVGW
Q2 202413 Jun 2025